Literature DB >> 29845439

The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.

Lingqun Ye1, Xuan Ni1, Zhen-Ao Zhao1,2, Wei Lei1,2, Shijun Hu3,4.   

Abstract

In recent decades, cardiovascular diseases have become the greatest health threat to human beings, and thus it is particularly important to explore the subtle underlying pathogenesis of cardiovascular diseases. Although many molecular pathways have been explored to be essential in the development of cardiovascular diseases, their clinical significances are still uncertain. With the emergence of induced pluripotent stem cells (iPSCs), a unique platform for cardiovascular diseases has been established to model cardiovascular diseases on specific genetic background in vitro. This review summarizes current progresses of iPSCs in cardiovascular disease modeling and drug testing. This review highlighted iPSC-based cardiovascular disease modeling and drug testing. The technical advances in iPSC-based researches and various clinically relevant applications are discussed. With further intensive research, iPSC technology will shape the future of clinical translational research in cardiovascular diseases.

Entities:  

Keywords:  Cardiovascular diseases; Disease modeling; Drug testing; Induced pluripotent stem cells

Mesh：

Substances：

Year:  2018        PMID： 29845439     DOI： 10.1007/s12265-018-9811-3

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN： 1937-5387            Impact factor:   4.132


  58 in total

Review 1.  Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.

Authors:  N Shaheen; A Shiti; L Gepstein
Journal:  Clin Pharmacol Ther       Date:  2017-08       Impact factor: 6.875

Review 2.  Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.

Authors:  Matthew F Peters; Sarah D Lamore; Liang Guo; Clay W Scott; Kyle L Kolaja
Journal:  Cardiovasc Toxicol       Date:  2015-04       Impact factor: 3.231

3.  Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy.

Authors:  Ning Sun; Masayuki Yazawa; Jianwei Liu; Leng Han; Veronica Sanchez-Freire; Oscar J Abilez; Enrique G Navarrete; Shijun Hu; Li Wang; Andrew Lee; Aleksandra Pavlovic; Shin Lin; Rui Chen; Roger J Hajjar; Michael P Snyder; Ricardo E Dolmetsch; Manish J Butte; Euan A Ashley; Michael T Longaker; Robert C Robbins; Joseph C Wu
Journal:  Sci Transl Med       Date:  2012-04-18       Impact factor: 17.956

4.  Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing.

Authors:  Yongming Wang; Ping Liang; Feng Lan; Haodi Wu; Leszek Lisowski; Mingxia Gu; Shijun Hu; Mark A Kay; Fyodor D Urnov; Rami Shinnawi; Joseph D Gold; Lior Gepstein; Joseph C Wu
Journal:  J Am Coll Cardiol       Date:  2014-08-05       Impact factor: 24.094

5.  High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry.

Authors:  Fabio Cerignoli; David Charlot; Ross Whittaker; Randy Ingermanson; Piyush Gehalot; Alex Savchenko; David J Gallacher; Rob Towart; Jeffrey H Price; Patrick M McDonough; Mark Mercola
Journal:  J Pharmacol Toxicol Methods       Date:  2012-08-25       Impact factor: 1.950

6.  Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.

Authors:  Ashish Mehta; Glen Lester Sequiera; Chrishan J A Ramachandra; Yuliansa Sudibyo; Yingying Chung; Jingwei Sheng; Keng Yean Wong; Teng Hong Tan; Philip Wong; Reginald Liew; Winston Shim
Journal:  Cardiovasc Res       Date:  2014-03-12       Impact factor: 10.787

7.  Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome.

Authors:  Deniz Akdis; Ardan M Saguner; Khooshbu Shah; Chuanyu Wei; Argelia Medeiros-Domingo; Arnold von Eckardstein; Thomas F Lüscher; Corinna Brunckhorst; H S Vincent Chen; Firat Duru
Journal:  Eur Heart J       Date:  2017-05-14       Impact factor: 29.983

Review 8.  Human engineered heart tissue as a model system for drug testing.

Authors:  Alexandra Eder; Ingra Vollert; Arne Hansen; Thomas Eschenhagen
Journal:  Adv Drug Deliv Rev       Date:  2015-05-27       Impact factor: 15.470

9.  Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian B Jung; Alessandra Moretti; Michael Mederos y Schnitzler; Laura Iop; Ursula Storch; Milena Bellin; Tatjana Dorn; Sandra Ruppenthal; Sarah Pfeiffer; Alexander Goedel; Ralf J Dirschinger; Melchior Seyfarth; Jason T Lam; Daniel Sinnecker; Thomas Gudermann; Peter Lipp; Karl-Ludwig Laugwitz
Journal:  EMBO Mol Med       Date:  2012-01-25       Impact factor: 12.137

10.  Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.

Authors:  Lu Han; Yang Li; Jason Tchao; Aaron D Kaplan; Bo Lin; You Li; Jocelyn Mich-Basso; Agnieszka Lis; Narmeen Hassan; Barry London; Glenna C L Bett; Kimimasa Tobita; Randall L Rasmusson; Lei Yang
Journal:  Cardiovasc Res       Date:  2014-09-10       Impact factor: 10.787
View more
  8 in total

Review 1.  Cardiomyocyte Maturation-the Road is not Obstructed.

Authors:  Yaning Wang; Miao Yu; Kaili Hao; Wei Lei; Mingliang Tang; Shijun Hu
Journal:  Stem Cell Rev Rep       Date:  2022-07-05       Impact factor: 5.739

2.  Computational translation of drug effects from animal experiments to human ventricular myocytes.

Authors:  Aslak Tveito; Karoline Horgmo Jæger; Mary M Maleckar; Wayne R Giles; Samuel Wall
Journal:  Sci Rep       Date:  2020-06-29       Impact factor: 4.379

3.  User-Friendly and Parallelized Generation of Human Induced Pluripotent Stem Cell-Derived Microtissues in a Centrifugal Heart-on-a-Chip.

Authors:  Oliver Schneider; Lisa Zeifang; Stefanie Fuchs; Carla Sailer; Peter Loskill
Journal:  Tissue Eng Part A       Date:  2019-05       Impact factor: 3.845

4.  Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β.

Authors:  Laura Padrón-Barthe; María Villalba-Orero; Jesús M Gómez-Salinero; Fernando Domínguez; Marta Román; Javier Larrasa-Alonso; Paula Ortiz-Sánchez; Fernando Martínez; Marina López-Olañeta; Elena Bonzón-Kulichenko; Jesús Vázquez; Carlos Martí-Gómez; Demetrio J Santiago; Belén Prados; Giovanna Giovinazzo; María Victoria Gómez-Gaviro; Silvia Priori; Pablo Garcia-Pavia; Enrique Lara-Pezzi
Journal:  Circulation       Date:  2019-09-05       Impact factor: 29.690

5.  Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.

Authors:  Karoline Horgmo Jæger; Samuel Wall; Aslak Tveito
Journal:  PLoS Comput Biol       Date:  2021-02-16       Impact factor: 4.475

Review 6.  Microengineered platforms for characterizing the contractile function of in vitro cardiac models.

Authors:  Wenkun Dou; Manpreet Malhi; Qili Zhao; Li Wang; Zongjie Huang; Junhui Law; Na Liu; Craig A Simmons; Jason T Maynes; Yu Sun
Journal:  Microsyst Nanoeng       Date:  2022-02-28       Impact factor: 7.127

7.  Rat-Induced Pluripotent Stem Cells-Derived Cardiac Myocytes in a Cell Culture Dish.

Authors:  Fatima Bianca A Dessouki; Pawan K Singal; Dinender K Singla
Journal:  Methods Mol Biol       Date:  2022

8.  Retinoic acid promotes metabolic maturation of human Embryonic Stem Cell-derived Cardiomyocytes.

Authors:  Shumei Miao; Dandan Zhao; Xiaoxiao Wang; Xuan Ni; Xing Fang; Miao Yu; Lingqun Ye; Jingsi Yang; Hongchun Wu; Xinglong Han; Lina Qu; Lei Li; Feng Lan; Zhenya Shen; Wei Lei; Zhen-Ao Zhao; Shijun Hu
Journal:  Theranostics       Date:  2020-08-01       Impact factor: 11.556
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.